UCSF Navigation Bar

UCSF Departments of Pathology & Laboratory Medicine Home Page

Lab Manual for UCSF Clinical Laboratories

Lab Manual for SFGH

Internal Resources

Click here for more information about laboratory operations and procedures

If you have additional questions regarding this test, please call: 415-353-1667

Search Our Test Menu

Epstein-Barr virus DNA, Quantitative, blood

Item Value
Approval req'd? No
Available Stat? No
Utilization Guidelines There is no indication for EBV testing on urine samples.
Test code EBVQT
Test group EBV
Performed by Microbiology
In House Availability Tuesday and Friday, day shift
Method Real time PCR
Collection Instructions Avoid hemolysis.
Container type Lavender top 6 mL size
Amount to Collect 4 mL blood
Sample type EDTA plasma
Preferred volume 2 mL plasma
Min. Volume 1 mL plasma
UCSF Rejection Criteria Collected in heparin tube, gross hemolysis.
Processing notes Separate plasma from cells and freeze at -70C within 6 hours of collection.
Units copies/mL
Normal range Not detected
Synonyms EBV PCR
Stability Room temperature up to 6 hours for whole blood; plasma frozen at -70°C for 1 month
Turn around times 1-4 days
Additional information This assay uses real-time PCR methodology to amplify a segment of the LMP2 gene, and is capable of accurate detection and quantitation from 1000 to 1 x 10e6 copies/mL. If detected with less than 1000 copies/mL, results will be reported as "Detected, < 1000 copies/mL". Change in virus DNA level over time is a better indicator of clinical significance than absolute copy number. This test was developed and its performance characteristics determined by the UCSF Clinical Laboratories. It has not been cleared or approved by the U. S. Food and Drug Administration.

This assay is most useful in identifying patients at risk for EBV lymphoproliferative diseases including post transplantation lymphoproliferative disease (PTLD) and certain lymphomas. Immunocompromised patients, including solid organ and hematopoietic stem cell transplant recipients and AIDS patients are at higher risk for clinical disease.

Studies suggest that rising copy numbers of EBV DNA in plasma indicate a risk of PTLD. In many of these patients, EBV DNA titers rise progressively, even before clinical evidence of disease. Rarely, patients with clinical EBV disease have DNA titers that are undetectable or below 1,000 copies/ml of plasma. This assay can also be used to monitor the efficacy of efforts designed to lower EBV levels.

No interference in assay performance was demonstrated in studies conducted on blood specimens containing CMV, HSV, or VZV.

Kinch A et al. (2007) Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogenic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction. Scandinavian Journal of Infectious Diseases 39: 235-244.

Perandin F et al. (2007) Comparison of commercial and in-house real-time PCR assays for quantification of Epstein-Barr virus (EBV) DNA in plasma. BMC Microbiology 7:22.
CPT coding 87799
LOINC code 36923-1
LDT or Mod FDA? Yes
Last Updated 8/7/2013 9:46:28 AM
Entry Number 330
UCSF home page UCSF home page About UCSF Search UCSF UCSF Medical Center